Fewer than 10% of patients who could benefit from GLP-1 drugs like Wegovy have access to them, warns the WHO as it releases its first advice on the medications.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is urging increased and just access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"The latest guidance recognises that obesity is a lifelong illness that can be managed with holistic and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major barriers to universal access to the treatments that can aid individuals in losing substantial body mass, says the agency.
Skinny Jab Scarcity
Despite the present most favorable outlook, the production of such drugs might only reach about 100 million people – less than 10% of the global need, as stated by the health organization.
The guideline calls on governments and firms to increase access, by approaches like patent sharing.
A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
The Way Obesity Injections Function
GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and enhance satiety so individuals consume fewer calories.
People commonly see weight reduction after several weeks of commencing the weekly injections.
Studies points to people may see weight return after a year of halting the drug, as their usual hunger come back.
To be above a healthy weight increases your chance for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and certain cancers.
Obesity impacts people in all nations and was linked to millions of deaths worldwide in 2024, according to the WHO.
